CL2024000642A1 - Anticuerpos del receptor antitransferrina y usos de los mismos - Google Patents
Anticuerpos del receptor antitransferrina y usos de los mismosInfo
- Publication number
- CL2024000642A1 CL2024000642A1 CL2024000642A CL2024000642A CL2024000642A1 CL 2024000642 A1 CL2024000642 A1 CL 2024000642A1 CL 2024000642 A CL2024000642 A CL 2024000642A CL 2024000642 A CL2024000642 A CL 2024000642A CL 2024000642 A1 CL2024000642 A1 CL 2024000642A1
- Authority
- CL
- Chile
- Prior art keywords
- transferrin receptor
- receptor antibodies
- antibodies
- methods
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239630P | 2021-09-01 | 2021-09-01 | |
| US202263388088P | 2022-07-11 | 2022-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000642A1 true CL2024000642A1 (es) | 2024-09-13 |
Family
ID=83508506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000642A CL2024000642A1 (es) | 2021-09-01 | 2024-03-01 | Anticuerpos del receptor antitransferrina y usos de los mismos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11827702B2 (OSRAM) |
| EP (1) | EP4396231A1 (OSRAM) |
| JP (1) | JP2024534880A (OSRAM) |
| KR (1) | KR20240107202A (OSRAM) |
| AU (1) | AU2022340568A1 (OSRAM) |
| CA (1) | CA3230796A1 (OSRAM) |
| CL (1) | CL2024000642A1 (OSRAM) |
| CO (1) | CO2024003577A2 (OSRAM) |
| CR (1) | CR20240139A (OSRAM) |
| IL (1) | IL311175A (OSRAM) |
| JO (1) | JOP20240042A1 (OSRAM) |
| MX (1) | MX2024002753A (OSRAM) |
| PE (1) | PE20240895A1 (OSRAM) |
| TW (1) | TW202328187A (OSRAM) |
| WO (1) | WO2023034409A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120882749A (zh) * | 2023-03-08 | 2025-10-31 | 渤健马萨诸塞州股份有限公司 | 抗转铁蛋白受体抗体及其用途 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| CN116735864B (zh) * | 2023-08-15 | 2023-11-10 | 迦进生物医药(上海)有限公司 | 评估TfR1抗体血液安全性的试剂盒 |
| TW202517685A (zh) * | 2023-10-26 | 2025-05-01 | 美商百健Ｍａ公司 | 抗運鐵蛋白受體抗體及其用途 |
| CN121517563A (zh) * | 2024-08-09 | 2026-02-13 | 东北制药集团股份有限公司 | 人源化的靶向TfR1的抗体及其应用 |
| WO2026076250A1 (en) * | 2024-10-03 | 2026-04-09 | Genentech, Inc. | Lipid nanoparticles for delivery to the cns from systemic administration |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| CA2081368A1 (en) | 1990-03-27 | 1991-09-28 | Ian S. Trowbridge | Method for inhibiting cell growth and compositions useful therefor |
| US5648469A (en) | 1992-04-20 | 1997-07-15 | The Salk Institute For Biological Studies | Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain |
| WO2005094364A2 (en) | 2004-03-31 | 2005-10-13 | Chimeric Technologies, Inc. | Iga antibody protein as a cytotoxic drug |
| CA2561830C (en) | 2004-03-31 | 2013-05-21 | Adnagen Ag | Monoclonal antibodies with specificity for fetal erythroid cells |
| WO2005111082A1 (en) | 2004-04-30 | 2005-11-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-tfr antibody. |
| AU2005252699B2 (en) | 2004-06-07 | 2010-12-23 | Macrogenics West, Inc. | Transferrin receptor antibodies |
| CZ200755A3 (cs) | 2004-07-26 | 2007-04-11 | Biogen Idec Ma Inc. | Peptidy protilátek anti-CD154 |
| JP2008531060A (ja) | 2005-03-04 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法 |
| US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| FR2953841B1 (fr) | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| FR2959416B1 (fr) | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
| WO2012075037A1 (en) | 2010-11-30 | 2012-06-07 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| CN103534272B (zh) | 2011-05-09 | 2016-05-11 | 株式会社英仙蛋白质科学 | 能够特异性识别转铁蛋白受体的抗体 |
| TWI450727B (zh) | 2011-12-29 | 2014-09-01 | 財團法人工業技術研究院 | 抗人類輸鐵蛋白受體的單域抗體與其應用 |
| US20130177579A1 (en) | 2012-01-06 | 2013-07-11 | Bioalliance C.V. | Anti-transferrin receptor antibodies and methods using same |
| RU2711552C2 (ru) | 2012-08-29 | 2020-01-17 | Ф. Хоффманн-Ля Рош Аг | Шаттл для гематоэнцефалического барьера |
| CA2893794C (en) | 2012-11-08 | 2021-11-09 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
| WO2014144060A1 (en) | 2013-03-15 | 2014-09-18 | Alper Biotech, Llc | Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof |
| EA038367B1 (ru) | 2013-05-20 | 2021-08-16 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ |
| US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
| EP3450557A1 (en) | 2013-12-25 | 2019-03-06 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
| JP6557664B2 (ja) | 2014-01-06 | 2019-08-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 一価の血液脳関門シャトルモジュール |
| JP6779876B2 (ja) | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| IL310251A (en) | 2015-05-04 | 2024-03-01 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof |
| CR20210429A (es) | 2015-06-24 | 2021-09-24 | Hoffmann La Roche | ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562) |
| KR20250073514A (ko) | 2015-06-24 | 2025-05-27 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체 |
| EP3325509B1 (en) | 2015-07-22 | 2020-12-16 | Inatherys | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders |
| TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| US20190240346A1 (en) | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
| US20190375819A1 (en) | 2016-10-29 | 2019-12-12 | Rhode Island Hospital | Glycosylated transferrin receptor 1 tumor antigen |
| NZ752703A (en) | 2016-12-26 | 2022-09-30 | Japan Chem Res | Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| CN110506054A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 经工程改造的多肽 |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| HUE063021T2 (hu) | 2017-08-10 | 2023-12-28 | Denali Therapeutics Inc | Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek |
| CN118638788A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| SG11202006433PA (en) | 2018-02-05 | 2020-08-28 | Jcr Pharmaceuticals Co Ltd | Method for delivering drug to muscle |
| US20220378934A1 (en) | 2018-08-02 | 2022-12-01 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| CA3108287A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| MX2021001282A (es) | 2018-08-02 | 2021-07-15 | Dyne Therapeutics Inc | Complejos dirigidos al músculo y sus usos. |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| EA202190418A1 (ru) | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии |
| EP3829594A4 (en) | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| US20210322562A1 (en) | 2018-08-02 | 2021-10-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating centronuclear myopathy |
| CA3108285A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating pompe disease |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US20210308274A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
| WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
| WO2021076856A1 (en) | 2019-10-18 | 2021-04-22 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3163608A1 (en) | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| IL294479A (en) | 2020-01-10 | 2022-09-01 | Dyne Therapeutics Inc | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy |
| US12624120B2 (en) * | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| WO2022020105A1 (en) | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| CA3202832A1 (en) | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
-
2022
- 2022-08-31 MX MX2024002753A patent/MX2024002753A/es unknown
- 2022-08-31 AU AU2022340568A patent/AU2022340568A1/en active Pending
- 2022-08-31 IL IL311175A patent/IL311175A/en unknown
- 2022-08-31 TW TW111132949A patent/TW202328187A/zh unknown
- 2022-08-31 US US17/900,161 patent/US11827702B2/en active Active
- 2022-08-31 CR CR20240139A patent/CR20240139A/es unknown
- 2022-08-31 PE PE2024000361A patent/PE20240895A1/es unknown
- 2022-08-31 CA CA3230796A patent/CA3230796A1/en active Pending
- 2022-08-31 EP EP22783097.3A patent/EP4396231A1/en active Pending
- 2022-08-31 WO PCT/US2022/042196 patent/WO2023034409A1/en not_active Ceased
- 2022-08-31 JP JP2024513785A patent/JP2024534880A/ja active Pending
- 2022-08-31 KR KR1020247010811A patent/KR20240107202A/ko active Pending
-
2023
- 2023-10-19 US US18/490,319 patent/US20240158494A1/en active Pending
-
2024
- 2024-02-29 JO JOJO/P/2024/0042A patent/JOP20240042A1/ar unknown
- 2024-03-01 CL CL2024000642A patent/CL2024000642A1/es unknown
- 2024-03-21 CO CONC2024/0003577A patent/CO2024003577A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240158494A1 (en) | 2024-05-16 |
| PE20240895A1 (es) | 2024-04-24 |
| CO2024003577A2 (es) | 2024-06-27 |
| IL311175A (en) | 2024-04-01 |
| EP4396231A1 (en) | 2024-07-10 |
| US20230131379A1 (en) | 2023-04-27 |
| MX2024002753A (es) | 2024-05-20 |
| KR20240107202A (ko) | 2024-07-08 |
| JP2024534880A (ja) | 2024-09-26 |
| CR20240139A (es) | 2024-06-14 |
| US11827702B2 (en) | 2023-11-28 |
| AU2022340568A1 (en) | 2024-03-28 |
| WO2023034409A1 (en) | 2023-03-09 |
| CA3230796A1 (en) | 2023-03-09 |
| JOP20240042A1 (ar) | 2024-02-29 |
| TW202328187A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024003577A2 (es) | Anticuerpos del receptor antitransferrina y usos de los mismos | |
| CL2023003607A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| CO2019007288A2 (es) | Anticuerpos anti-ox40 y sus usos | |
| CO2019003154A2 (es) | Anticuerpos anti-pd-1 y sus usos | |
| MX2020014243A (es) | Neoantigenos y usos de los mismos. | |
| MX2020006689A (es) | Composiciones de vcar y metodos de uso. | |
| MX2020013977A (es) | Proteínas quiméricas transmembrana y usos de las mismas. | |
| CO2021012719A2 (es) | Métodos para producción de células car-nk y uso de las mismas | |
| CO2019012473A2 (es) | Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos | |
| CL2018000358A1 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| CO6351800A2 (es) | Anticuerpos anti -il -17a/il -17f de reactividad cruzada y metodos de uso de los mismos | |
| BR112022025221A2 (pt) | Sistemas de expressão de baculovírus | |
| ECSP11011344A (es) | Nuevos anticuerpos anti-?5?1 y sus usos | |
| CL2016001256A1 (es) | Composiciones y métodos para anticuerpos dirigidos factor de p (divisional de sol. n° 1640-14). | |
| CL2022003684A1 (es) | Agentes de unión a lair-1 y métodos para su uso | |
| MX2023009238A (es) | Nuevos anticuerpos anti-cd24. | |
| CU20180047A7 (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación | |
| MX2021004925A (es) | Variantes de adn-polimerasa modificadas. | |
| AR115695A1 (es) | Moléculas proteicas multifuncionales que comprenden decorina y uso de estas | |
| CO2025007355A2 (es) | Anticuerpo anti-trem2 y usos del mismo | |
| CO2023014622A2 (es) | Conjugados de anticuerpo-fármaco anti-c-met | |
| MX2021011887A (es) | Receptores de antigeno quimerico humanizados anti-claudin 18.2 y usos de los mismos. | |
| MX2021014973A (es) | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. | |
| NI202000087A (es) | Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
| CO2024007674A2 (es) | Anticuerpo anti-trem2 y usos del mismo |